<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
08.07.2019 17:08:00

Why Geron Corporation Stock Bolted Higher in the First Half of 2019

Shares of the prerevenue biotech Geron Corporation (NASDAQ: GERN) gained an astounding 41% during the first six months of 2019, according to data from S&P Global Market Intelligence. What caused investors to pile into this clinical-stage biotech stock in the first half of the year?Geron's stock has been marching higher in response to the news that its telomerase inhibitor, imetelstat, will enter a pivotal-stage trial for the rare blood disorder known as lower-risk myelodysplastic syndromes (MDS) this summer.Image Source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Geron Corp.mehr Analysen

03.09.19 Geron Buy H.C. Wainwright & Co.
15.08.19 Geron Overweight Cantor Fitzgerald
09.04.19 Geron Buy Needham & Company, LLC
31.01.19 Geron Buy B. Riley FBR
02.10.18 Geron Neutral B. Riley FBR

Eintrag hinzufügen

SMI auf Rekordkurs – Notenbanken im Fokus | BX Swiss TV

Aktien in diesem Artikel

Geron Corp. 1.79 -7.39% Geron Corp.

Finanzen.net News

pagehit